Effect of 6R-BH4 Treatment in Coronary Artery Disease (OXBIO Study)

Exclusion Criteria

• •Inability to provide informed consent
• •Female subject who is pregnant, lactating or planning pregnancy during course of study
• •Prior clinical diagnosis of heart failure requiring diuretic therapy with evidence of severe left ventricular dysfunction
• •Recent acute coronary event (\<4 weeks)
• •Emergency CABG
• •Newly diagnosed diabetes mellitus (\<1 month)
• •Body weight \>130kg
• •Impaired renal function (creatinine \>180umol/l)
• •Elevated liver function tests (ALT \>50umol/l or AST \>2x normal)
• •Pacemakers, ICDs or metallic implants not compatible with MRI scanning
• •Subjects receiving experimental medications or participating in another study
• •Terminally ill subjects
• •Known hypersensitivity to 6R-BH4
• •Concomitant treatment with methotrexate, levodopa, PDE-3 or PDE-5 inhibitors